Ibrahim Alnadhari
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ibrahim Alnadhari has a total of 108 co-authors. Here are the top co-authors by number of shared publications:
Ahmad Shamsodini
Urology Section, Department of Surgery, Al Wakra Hospital, Hamad Medical Corporation, Al Wakra, Qatar
8 shared publicationsOmar Ali
Urology Section, Department of Surgery, Al Wakra Hospital, Hamad Medical Corporation, Al Wakra, Qatar
7 shared publicationsOsama Abdeljaleel
Urology Section, Department of Surgery, Al Wakra Hospital, Hamad Medical Corporation, Al Wakra, Qatar
6 shared publications- Faisal Ahmed
Department of Urology, Faculty of Medicine, Ibb University, Ibb
5 shared publications Morshed Salah
Department of Urology, Al Wakra Hospital, Hamad Medical Corporation, Doha, Qatar
5 shared publications- Ahmad Shamsodini
Urology Department, Hamad General Hospital, Doha, Qatar
4 shared publications
Latest Publications
- Open Access
- 29 September 2026
- Published by Springer Nature in International Journal Of Impotence Research
- p. 1-5
Zero-touch technique: a new paradigm in penile prosthesis surgery enabled by a sterile genital barrier system
Penile prosthesis (PP) implantation remains the most definitive treatment for medication-refractory erectile dysfunction (ED). Despite reductions in infection rates achieved through improved PP coatings, antimicrobial protocols, and refined surgical techniques, PP infection continues to impose clinical and economic burdens. To overcome these intrinsic constraints, we introduce the Zero-Touch Technique (ZTT), a fundamentally new operative paradigm enabled by a purpose-designed sterile genital barrier system. This system consists of an anatomically contoured non-adhesive penile sheath, an adhesive scrotal and suprapubic isolation layer, and lateral anchoring wings that create a 360-degree sealed sterile field. Applied immediately after antiseptic preparation and before incision, the barrier completely isolates the penis and scrotum, allowing all subsequent steps—including exposure, dilation, implantation, pump placement, and device cycling—to occur without contact with hair-bearing genital skin. ZTT has the potential to improve infection prevention in PP surgery and may contribute to establishing a new sterility standard pending further validation.
- 29 September 2026
- Published by Springer Nature in International Journal Of Impotence Research
- p. 1-5
Open AccessZero-touch technique: a new paradigm in penile prosthesis surgery enabled by a sterile genital barrier system
Penile prosthesis (PP) implantation remains the most definitive treatment for medication-refractory erectile dysfunction (ED). Despite reductions in infection rates achieved through improved PP coatings, antimicrobial protocols, and refined surgical techniques, PP infection continues to impose clinical and economic burdens. To overcome these intrinsic constraints, we introduce the Zero-Touch Technique (ZTT), a fundamentally new operative paradigm enabled by a purpose-designed sterile genital barrier system. This system consists of an anatomically contoured non-adhesive penile sheath, an adhesive scrotal and suprapubic isolation layer, and lateral anchoring wings that create a 360-degree sealed sterile field. Applied immediately after antiseptic preparation and before incision, the barrier completely isolates the penis and scrotum, allowing all subsequent steps—including exposure, dilation, implantation, pump placement, and device cycling—to occur without contact with hair-bearing genital skin. ZTT has the potential to improve infection prevention in PP surgery and may contribute to establishing a new sterility standard pending further validation.
- Open Access
- 1 January 2026
- Published by Hamad bin Khalifa University Press (HBKU Press) in Qatar Medical Journal
- Vol. 2026 (1) , 16
Unexpected course of urethroplasty in patient with penile prosthesis
Introduction: Urethral stricture disease is a complex and debilitating condition that significantly impairs urinary function and quality of life. Urethroplasty remains the gold-standard treatment, especially for complex, long-segment, or recurrent strictures. However, performing urethroplasty in patients with penile prostheses presents unique surgical challenges due to the associated anatomical and vascular considerations. Case presentation: We report the case of a male patient with a history of penile prosthesis implantation nine years earlier who presented with a recurrent bulbar urethral stricture. The patient underwent excision and primary anastomosis (EPA) urethroplasty. Postoperatively, he developed significant urinary leakage at the anastomotic site, which was confirmed by pericatheter urethrogram, and urine culture grew extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli. The condition was managed conservatively with intravenous antibiotics and suprapubic catheter placement, resulting in resolution of the leakage and preservation of prosthesis function. Discussion: This case highlights the interplay between urethral vascular compromise and the presence of a penile prosthesis, both of which can increase the risk of complications following urethroplasty. Infection, impaired healing, and altered anatomy contribute to the complexity of surgical management. Although the urethral stricture was amenable to EPA, the healing process was likely adversely affected by local infection and compromised blood supply. Conclusion: Urethroplasty in patients with a penile prosthesis requires a tailored approach that accounts for altered anatomy and vascularity. In this case, the EPA was complicated by infection and urine leakage; however, conservative management resulted in successful healing, restoration of urinary flow, and preservation of prosthesis function. This case highlights the importance of careful surgical planning and flexible postoperative care.
- 1 January 2026
- Published by Hamad bin Khalifa University Press (HBKU Press) in Qatar Medical Journal
- Vol. 2026 (1) , 16
Open AccessUnexpected course of urethroplasty in patient with penile prosthesis
Introduction: Urethral stricture disease is a complex and debilitating condition that significantly impairs urinary function and quality of life. Urethroplasty remains the gold-standard treatment, especially for complex, long-segment, or recurrent strictures. However, performing urethroplasty in patients with penile prostheses presents unique surgical challenges due to the associated anatomical and vascular considerations. Case presentation: We report the case of a male patient with a history of penile prosthesis implantation nine years earlier who presented with a recurrent bulbar urethral stricture. The patient underwent excision and primary anastomosis (EPA) urethroplasty. Postoperatively, he developed significant urinary leakage at the anastomotic site, which was confirmed by pericatheter urethrogram, and urine culture grew extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli. The condition was managed conservatively with intravenous antibiotics and suprapubic catheter placement, resulting in resolution of the leakage and preservation of prosthesis function. Discussion: This case highlights the interplay between urethral vascular compromise and the presence of a penile prosthesis, both of which can increase the risk of complications following urethroplasty. Infection, impaired healing, and altered anatomy contribute to the complexity of surgical management. Although the urethral stricture was amenable to EPA, the healing process was likely adversely affected by local infection and compromised blood supply. Conclusion: Urethroplasty in patients with a penile prosthesis requires a tailored approach that accounts for altered anatomy and vascularity. In this case, the EPA was complicated by infection and urine leakage; however, conservative management resulted in successful healing, restoration of urinary flow, and preservation of prosthesis function. This case highlights the importance of careful surgical planning and flexible postoperative care.
- Open Access
- 22 October 2025
- Published by PAGEPress Publications in Archivio Italiano di Urologia e Andrologia
- Vol. 97 (4) , 14265
Performance of ‘Triple-D’ and ‘Quadruple-D’ scores compared to a regression-based predictive model for treatment outcomes in extracorporeal shock wave lithotripsy
Background: Extracorporeal shock wave lithotripsy (ESWL) is a widely utilized, noninvasive treatment for renal and ureteric stones. Accurate prediction of treatment outcomes is essential for improving patient counseling and optimizing clinical management. Established scoring systems, such as the ‘Triple-D’ score – which incorporates stone Density, Diameter, and skin-to-stone Distance –and the ‘Quadruple-D’ score – which adds factors like stone location or hydronephrosis status – are used to stratify patients by risk. However, these tools have limitations in predictive accuracy. This study aimed to evaluate and compare the predictive performances of the Triple-D and Quadruple-D scores against a novel regression-based model for ESWL outcomes.Methods: A retrospective study was conducted on 1,000 adult patients treated with ESWL using the Dornier Compact Delta® III Pro lithotripter from May 2022 to November 2023. Key predictors of ESWL failure were identified using multivariable logistic regression with internal validation. Predictive performances were compared using receiver operating characteristic (ROC) analysis, with statistical differences assessed by DeLong’s test. Model calibration and clinical utility were examined through calibration plots and decision curve analysis (DCA).Results: ESWL treatment success was achieved in 87.5% of patients. Independent predictors of failure included prior urologic intervention (adjusted odds ratio [aOR] 2.64, 95% CI 1.75-3.99), multiple stones (aOR 0.45, 95% CI 0.24-0.77), higher stone density (per 100 Hounsfield Units increase; p<0.001), and increased skin-to-stone distance (per cm; aOR 1.18, 95% CI 1.06-1.30). The regression-based model showed superior discrimination (AUC 0.92) compared to the Quadruple-D (AUC 0.81, p=0.01) and Triple-D (AUC 0.72, p<0.001) scores. Calibration and DCA confirmed the model’s improved accuracy and clinical benefit.Conclusions: The regression-based model outperforms existing Triple-D and Quadruple-D scores in predicting ESWL failure, providing enhanced individualized risk stratification. This may facilitate better patient selection and treatment planning. Prospective validation is warranted.
- 22 October 2025
- Published by PAGEPress Publications in Archivio Italiano di Urologia e Andrologia
- Vol. 97 (4) , 14265
Open AccessPerformance of ‘Triple-D’ and ‘Quadruple-D’ scores compared to a regression-based predictive model for treatment outcomes in extracorporeal shock wave lithotripsy
Background: Extracorporeal shock wave lithotripsy (ESWL) is a widely utilized, noninvasive treatment for renal and ureteric stones. Accurate prediction of treatment outcomes is essential for improving patient counseling and optimizing clinical management. Established scoring systems, such as the ‘Triple-D’ score – which incorporates stone Density, Diameter, and skin-to-stone Distance –and the ‘Quadruple-D’ score – which adds factors like stone location or hydronephrosis status – are used to stratify patients by risk. However, these tools have limitations in predictive accuracy. This study aimed to evaluate and compare the predictive performances of the Triple-D and Quadruple-D scores against a novel regression-based model for ESWL outcomes.Methods: A retrospective study was conducted on 1,000 adult patients treated with ESWL using the Dornier Compact Delta® III Pro lithotripter from May 2022 to November 2023. Key predictors of ESWL failure were identified using multivariable logistic regression with internal validation. Predictive performances were compared using receiver operating characteristic (ROC) analysis, with statistical differences assessed by DeLong’s test. Model calibration and clinical utility were examined through calibration plots and decision curve analysis (DCA).Results: ESWL treatment success was achieved in 87.5% of patients. Independent predictors of failure included prior urologic intervention (adjusted odds ratio [aOR] 2.64, 95% CI 1.75-3.99), multiple stones (aOR 0.45, 95% CI 0.24-0.77), higher stone density (per 100 Hounsfield Units increase; p<0.001), and increased skin-to-stone distance (per cm; aOR 1.18, 95% CI 1.06-1.30). The regression-based model showed superior discrimination (AUC 0.92) compared to the Quadruple-D (AUC 0.81, p=0.01) and Triple-D (AUC 0.72, p<0.001) scores. Calibration and DCA confirmed the model’s improved accuracy and clinical benefit.Conclusions: The regression-based model outperforms existing Triple-D and Quadruple-D scores in predicting ESWL failure, providing enhanced individualized risk stratification. This may facilitate better patient selection and treatment planning. Prospective validation is warranted.
- Open Access
- 30 September 2025
- Published by PAGEPress Publications in Archivio Italiano di Urologia e Andrologia
- Vol. 97 (3) , 14129
Epidemiology and antimicrobial resistance of uropathogens in a tertiary care setting in Yemen: a retrospective study
Background: Urinary tract infections (UTIs) are a major global health concern, particularly in resource-limited regions where antimicrobial resistance (AMR) is increasingly prevalent. This study aimed to describe the demographic characteristics, pathogen distribution, and antimicrobial resistance patterns among UTI patients, and to identify clinical predictors of multidrug-resistant (MDR) and extensively drug-resistant (XDR) infections.Methods: A retrospective analysis was conducted on 216 clinically confirmed UTI cases processed at the Infectious Bacteriology and Biochemistry Laboratory affiliated with IBB University between January 2023 and September 2024. Data collected included patient demographics, clinical symptoms, comorbidities, bacterial isolates, and antimicrobial susceptibility profiles. MDR and XDR were classified according to internationally recognized definitions. Univariate and multivariate logistic regression analyses were performed to identify independent predictors of MDR/XDR infections.Results: The majority of patients were adults aged 15-65 years (83.3%, n=180), with a slight male predominance (53.2%, n=115). Escherichia coli was the most frequently isolated pathogen (29.6%, n=64), followed by Staphylococcus aureus (19.0%, n=41) and Pseudomonas aeruginosa (6.0%, n=13). A substantial proportion of isolates exhibited MDR or XDR phenotypes (80.1%, n=173). Among E. coli isolates, resistance rates to ciprofloxacin and ceftriaxone exceeded 60%. Notably, all Klebsiella pneumoniae isolates were MDR (100%), and 92.3% of P. aeruginosa isolates were MDR. Nitrofurantoin and carbapenems demonstrated relatively higher susceptibility rates. Multivariate analysis identified prior hospitalization (adjusted odds ratio [aOR] = 3.15; 95% CI:1.50-6.60; p=0.002) and E. coli infection (aOR = 2.41; 95%CI: 1.02–5.70; p=0.04) as significant predictors of MDR/XDR infections.Conclusions: The high prevalence of MDR and XDR uropathogens, particularly E. coli, underscores the urgent need for sustained antimicrobial resistance surveillance and stewardship programs in resource-limited settings. Identifying key clinical predictors can inform empirical treatment strategies, improve patient outcomes, and help contain the spread of resistant organisms.
- 30 September 2025
- Published by PAGEPress Publications in Archivio Italiano di Urologia e Andrologia
- Vol. 97 (3) , 14129
Open AccessEpidemiology and antimicrobial resistance of uropathogens in a tertiary care setting in Yemen: a retrospective study
Background: Urinary tract infections (UTIs) are a major global health concern, particularly in resource-limited regions where antimicrobial resistance (AMR) is increasingly prevalent. This study aimed to describe the demographic characteristics, pathogen distribution, and antimicrobial resistance patterns among UTI patients, and to identify clinical predictors of multidrug-resistant (MDR) and extensively drug-resistant (XDR) infections.Methods: A retrospective analysis was conducted on 216 clinically confirmed UTI cases processed at the Infectious Bacteriology and Biochemistry Laboratory affiliated with IBB University between January 2023 and September 2024. Data collected included patient demographics, clinical symptoms, comorbidities, bacterial isolates, and antimicrobial susceptibility profiles. MDR and XDR were classified according to internationally recognized definitions. Univariate and multivariate logistic regression analyses were performed to identify independent predictors of MDR/XDR infections.Results: The majority of patients were adults aged 15-65 years (83.3%, n=180), with a slight male predominance (53.2%, n=115). Escherichia coli was the most frequently isolated pathogen (29.6%, n=64), followed by Staphylococcus aureus (19.0%, n=41) and Pseudomonas aeruginosa (6.0%, n=13). A substantial proportion of isolates exhibited MDR or XDR phenotypes (80.1%, n=173). Among E. coli isolates, resistance rates to ciprofloxacin and ceftriaxone exceeded 60%. Notably, all Klebsiella pneumoniae isolates were MDR (100%), and 92.3% of P. aeruginosa isolates were MDR. Nitrofurantoin and carbapenems demonstrated relatively higher susceptibility rates. Multivariate analysis identified prior hospitalization (adjusted odds ratio [aOR] = 3.15; 95% CI:1.50-6.60; p=0.002) and E. coli infection (aOR = 2.41; 95%CI: 1.02–5.70; p=0.04) as significant predictors of MDR/XDR infections.Conclusions: The high prevalence of MDR and XDR uropathogens, particularly E. coli, underscores the urgent need for sustained antimicrobial resistance surveillance and stewardship programs in resource-limited settings. Identifying key clinical predictors can inform empirical treatment strategies, improve patient outcomes, and help contain the spread of resistant organisms.
- Open Access
- 4 June 2025
- Published by AVES YAYINCILIK A.Ş. in Urology Research and Practice
- Vol. 51 (2) , 66-69
Drug-Coated Balloon (Optilume®) for the Management of Bulbar Urethral Stricture, Our Experience
Objective: The drug (paclitaxel)-coated balloon (DCB) Optilume® is designed to dilate the urethral lumen via balloon dilation while also promoting long-term urethral patency through the targeted and circumferential delivery of paclitaxel. As an antimi totic agent, paclitaxel functions by inhibiting cellular proliferation and migration. The objective of this study is to assess the safety and efficacy of this DCB in managing bul bar urethral strictures. Methods: This study is a retrospective study, involving 19 patients who underwent treatment with DCB for bulbar strictures. Patients’ characteristics, preoperative and postoperative maximum flow rates (Qmax), and the duration until recurrence were recorded. Postoperative complications were also noted. Results: Success was achieved in 15 out of 19 patients (78.9%) with a median follow up period of 352 days. The mean maximum urine flow rate preoperatively was 5 mL/s (with a range of 4.00-6.50 mL/s). Subsequent mean flow rates at 3 months, 6 months, 12 months, and 24 months post-treatment were 32 mL/s, 32 mL/s, 24 mL/s, and 20 mL/s, respectively. Notably, there was no recurrence among the 7 patients without previous surgical interventions (47%, P-value .01). The mean duration of stricture-free survival following surgery was 648 days (approximately 21.6 months) (95% CI 500.4 700.2). Importantly, no complications were reported throughout the study. Conclusion: The use of DCB for managing bulbar urethral stricture demonstrated a suc cess rate of 78.9%. Patients without a history of urethral surgery exhibited significantly improved treatment outcomes. Furthermore, the study reported no significant compli cations associated with the use of DCB. Cite this article as: Alnadhari I, Alshrani M, Alhattami A, et al. Drug-coated balloon (optilume®) for the management of bulbar urethral stricture, our experience. Urol Res Pract. 2025;51(2):66-69.
- 4 June 2025
- Published by AVES YAYINCILIK A.Ş. in Urology Research and Practice
- Vol. 51 (2) , 66-69
Open AccessDrug-Coated Balloon (Optilume®) for the Management of Bulbar Urethral Stricture, Our Experience
Objective: The drug (paclitaxel)-coated balloon (DCB) Optilume® is designed to dilate the urethral lumen via balloon dilation while also promoting long-term urethral patency through the targeted and circumferential delivery of paclitaxel. As an antimi totic agent, paclitaxel functions by inhibiting cellular proliferation and migration. The objective of this study is to assess the safety and efficacy of this DCB in managing bul bar urethral strictures. Methods: This study is a retrospective study, involving 19 patients who underwent treatment with DCB for bulbar strictures. Patients’ characteristics, preoperative and postoperative maximum flow rates (Qmax), and the duration until recurrence were recorded. Postoperative complications were also noted. Results: Success was achieved in 15 out of 19 patients (78.9%) with a median follow up period of 352 days. The mean maximum urine flow rate preoperatively was 5 mL/s (with a range of 4.00-6.50 mL/s). Subsequent mean flow rates at 3 months, 6 months, 12 months, and 24 months post-treatment were 32 mL/s, 32 mL/s, 24 mL/s, and 20 mL/s, respectively. Notably, there was no recurrence among the 7 patients without previous surgical interventions (47%, P-value .01). The mean duration of stricture-free survival following surgery was 648 days (approximately 21.6 months) (95% CI 500.4 700.2). Importantly, no complications were reported throughout the study. Conclusion: The use of DCB for managing bulbar urethral stricture demonstrated a suc cess rate of 78.9%. Patients without a history of urethral surgery exhibited significantly improved treatment outcomes. Furthermore, the study reported no significant compli cations associated with the use of DCB. Cite this article as: Alnadhari I, Alshrani M, Alhattami A, et al. Drug-coated balloon (optilume®) for the management of bulbar urethral stricture, our experience. Urol Res Pract. 2025;51(2):66-69.
- Open Access
- 19 May 2025
- Published by PAGEPress Publications in Archivio Italiano di Urologia e Andrologia
- p. 13480
Safety of large reservoirs in inflatable penile prosthesis surgery
Introduction: The use of inflatable penile prostheses (IPP) has become a well-established treatment for erectile dysfunction, offering significant improvements in the quality of life for many patients. The reservoir site and size in IPP surgery are areas of ongoing research and debate. This study aims to evaluate the outcomes associated with the use of large reservoirs in IPP, focusing on both the surgical techniques and postoperative complications. Materials and methods: Our study is a retrospective study of 60 patients who underwent inflatable penile prosthesis (IPP) with large reservoir irrespective of the size of the prosthesis in Al Wakra Hospital from the period of 1st of January 2022 to 30th of August 2024. Results: Successful insertion of the large reservoir was carried out in all patients from the same penoscrotal incision. There was no recorded migration, urethral injury, infection, device failure, pain, erosion or LUTS in our patients. Revision was done in one patient.Conclusions: The use of large-volume reservoirs in inflatable penile prosthesis (IPP) surgery demonstrates a favorable safety profile, with no significant increase in complication rates compared to standard reservoir sizes.
- 19 May 2025
- Published by PAGEPress Publications in Archivio Italiano di Urologia e Andrologia
- p. 13480
Open AccessSafety of large reservoirs in inflatable penile prosthesis surgery
Introduction: The use of inflatable penile prostheses (IPP) has become a well-established treatment for erectile dysfunction, offering significant improvements in the quality of life for many patients. The reservoir site and size in IPP surgery are areas of ongoing research and debate. This study aims to evaluate the outcomes associated with the use of large reservoirs in IPP, focusing on both the surgical techniques and postoperative complications. Materials and methods: Our study is a retrospective study of 60 patients who underwent inflatable penile prosthesis (IPP) with large reservoir irrespective of the size of the prosthesis in Al Wakra Hospital from the period of 1st of January 2022 to 30th of August 2024. Results: Successful insertion of the large reservoir was carried out in all patients from the same penoscrotal incision. There was no recorded migration, urethral injury, infection, device failure, pain, erosion or LUTS in our patients. Revision was done in one patient.Conclusions: The use of large-volume reservoirs in inflatable penile prosthesis (IPP) surgery demonstrates a favorable safety profile, with no significant increase in complication rates compared to standard reservoir sizes.
- Open Access
- 5 May 2025
- Published by PAGEPress Publications in Archivio Italiano di Urologia e Andrologia
Complications in emergency ureteroscopy for ureteral stone treatment: a retrospective study
Background: Data on complications associated with emergency ureteroscopy for ureteral stones are limited, particularly in developing countries. This study investigates factors contributing to complications in emergency ureteroscopy utilizing a pneumatic semirigid ureteroscope (URS). Materials and methods: This retrospective analysis included 266 patients with ureteral stones who underwent emergency ureteroscopy using a pneumatic semirigid URS from 2018 to 2023. We extracted comprehensive data on patient demographics, stone characteristics, intraoperative and postoperative complications, and stone-free rate (SFR) from medical records, subsequently subjected to statistical analysis. Factors linked to complications were explored through univariate and multivariate analyses. Results: The mean stone size was 9.1 ± 4.9 mm, with the majority (n = 181, 71.3%) located in the mid-ureter. The mean operative duration was 57.7 ± 7.3 min. The overall complication rate was 10.2%, with intraoperative complications in 16 patients (6.0%), including mucosal damage (3.4%), stone up-migration (3.0%), and one ureteral perforation (0.4%). Postoperative complications occurred in 13 patients (4.9%), primarily fever (2.6%), followed by hematuria (1.1%). Additional complications included febrile urinary tract infections (UTIs), pyelonephritis, and one mortality. The overall SFR was 85.3%, with 39 patients (14.7%) demonstrating residual stones. Significant predictive factors for complications included larger stone size (Adjusted Odds Ratio [AOR]: 1.3; 95% Confidence Interval [CI]: 1.15-1.39, p<0.0001) and proximal ureteral stones (AOR: 4.9; 95% CI: 1.31-18.23, p=0.0182). Conclusions: Emergency ureteroscopy using a semirigid URS demonstrated favorable outcomes in treating ureteral stones, characterized by minimal complications and an acceptable SFR. Emphasizing appropriate instrument selection, surgical expertise, and technique is crucial in minimizing adverse events, particularly for large and upper ureteral stones.
- 5 May 2025
- Published by PAGEPress Publications in Archivio Italiano di Urologia e Andrologia
Open AccessComplications in emergency ureteroscopy for ureteral stone treatment: a retrospective study
Background: Data on complications associated with emergency ureteroscopy for ureteral stones are limited, particularly in developing countries. This study investigates factors contributing to complications in emergency ureteroscopy utilizing a pneumatic semirigid ureteroscope (URS). Materials and methods: This retrospective analysis included 266 patients with ureteral stones who underwent emergency ureteroscopy using a pneumatic semirigid URS from 2018 to 2023. We extracted comprehensive data on patient demographics, stone characteristics, intraoperative and postoperative complications, and stone-free rate (SFR) from medical records, subsequently subjected to statistical analysis. Factors linked to complications were explored through univariate and multivariate analyses. Results: The mean stone size was 9.1 ± 4.9 mm, with the majority (n = 181, 71.3%) located in the mid-ureter. The mean operative duration was 57.7 ± 7.3 min. The overall complication rate was 10.2%, with intraoperative complications in 16 patients (6.0%), including mucosal damage (3.4%), stone up-migration (3.0%), and one ureteral perforation (0.4%). Postoperative complications occurred in 13 patients (4.9%), primarily fever (2.6%), followed by hematuria (1.1%). Additional complications included febrile urinary tract infections (UTIs), pyelonephritis, and one mortality. The overall SFR was 85.3%, with 39 patients (14.7%) demonstrating residual stones. Significant predictive factors for complications included larger stone size (Adjusted Odds Ratio [AOR]: 1.3; 95% Confidence Interval [CI]: 1.15-1.39, p<0.0001) and proximal ureteral stones (AOR: 4.9; 95% CI: 1.31-18.23, p=0.0182). Conclusions: Emergency ureteroscopy using a semirigid URS demonstrated favorable outcomes in treating ureteral stones, characterized by minimal complications and an acceptable SFR. Emphasizing appropriate instrument selection, surgical expertise, and technique is crucial in minimizing adverse events, particularly for large and upper ureteral stones.
- Open Access
- 1 May 2025
- Published by Taylor & Francis in Research and Reports in Urology
- Vol. ume 17, 139-152
Assessing the Predictive Accuracy of the S.T.O.N.E. Score for Stone-Free Rates in Semirigid Pneumatic Ureteral Lithotripsy: Implications for Validation
Background: The lack of reliable predictive tools for outcomes following ureteral lithotripsy (ULT) presents significant challenges in clinical decision-making. This study evaluates the efficacy of the S.T.O.N.E. score—an assessment incorporating Size, Topography, Obstruction, Number, and Hounsfield units (HU)—in predicting the likelihood of achieving a stone-free rate (SFR) in patients undergoing semirigid pneumatic ULT. Methods: This retrospective analysis involved 266 patients with ureteral stones who underwent ULT at IBB University Hospitals from April 2021 to September 2023. The S.T.O.N.E. score was derived from preoperative CT scans, and a nomogram was created to predict SFR failure. Discrimination and calibration were assessed using the area under the receiver operating characteristic curve (AUC) and calibration curve, while decision curve analysis (DCA) evaluated clinical utility. Results: The cohort’s mean age was 47.7 ± 15 years, with a predominance of males (72.2%). The mean S.T.O.N.E. score was 7.8 ± 1.8. The overall SFR of 85.3% and residual stones were detected in 39 patients (14.7%). Multivariate analysis identified higher HU (AOR: 1.01; 95% CI: 1.00– 1.01; P < 0.001), proximal stone location (AOR: 15.13; 95% CI: 1.52– 51.13; P = 0.020), moderate (AOR: 34.23; 95% CI: 8.28– 141.45; P < 0.001) and severe hydronephrosis (AOR: 33.75; 95% CI: 4.55– 250.36; P = 0.0006), and larger stone size (AOR: 1.51; 95% CI: 1.30– 1.75; P < 0.0001) as significant predictors of SFR failure. The S.T.O.N.E. score effectively predicts SFR failure, with an optimal threshold of > 8 achieving 85.0% accuracy. The model demonstrated 72.0% sensitivity, 81.0% specificity, and strong calibration. DCA indicated clinical utility, differentiating between low- and high-risk patients based on their S.T.O.N.E. scores. Conclusion: The S.T.O.N.E. score is a valuable tool for predicting post-ULT SFR, aiding preoperative decision-making and potentially improving surgical outcomes by identifying high-risk patients. Further validation in diverse populations is needed to confirm its clinical utility. Plain Language Summary: Ureteral lithotripsy (ULT) is a procedure used to treat ureteral stones; however, predicting the success of this treatment remains challenging for urologists. This study evaluates the S.T.O.N.E. score, a tool designed to estimate a patient’s likelihood of achieving stone-free status following ULT by considering factors such as stone size and location. Researchers analyzed data from 266 patients who underwent ULT at IBB University Hospitals between April 2021 and September 2023. The findings indicate that the S.T.O.N.E. score effectively predicts the presence of residual stones post-treatment. These results suggest that the score may assist urologists in making more informed decisions prior to surgery, particularly for patients at elevated risk. However, further research is necessary to validate its applicability across diverse patient populations.
- 1 May 2025
- Published by Taylor & Francis in Research and Reports in Urology
- Vol. ume 17, 139-152
Open AccessAssessing the Predictive Accuracy of the S.T.O.N.E. Score for Stone-Free Rates in Semirigid Pneumatic Ureteral Lithotripsy: Implications for Validation
Background: The lack of reliable predictive tools for outcomes following ureteral lithotripsy (ULT) presents significant challenges in clinical decision-making. This study evaluates the efficacy of the S.T.O.N.E. score—an assessment incorporating Size, Topography, Obstruction, Number, and Hounsfield units (HU)—in predicting the likelihood of achieving a stone-free rate (SFR) in patients undergoing semirigid pneumatic ULT. Methods: This retrospective analysis involved 266 patients with ureteral stones who underwent ULT at IBB University Hospitals from April 2021 to September 2023. The S.T.O.N.E. score was derived from preoperative CT scans, and a nomogram was created to predict SFR failure. Discrimination and calibration were assessed using the area under the receiver operating characteristic curve (AUC) and calibration curve, while decision curve analysis (DCA) evaluated clinical utility. Results: The cohort’s mean age was 47.7 ± 15 years, with a predominance of males (72.2%). The mean S.T.O.N.E. score was 7.8 ± 1.8. The overall SFR of 85.3% and residual stones were detected in 39 patients (14.7%). Multivariate analysis identified higher HU (AOR: 1.01; 95% CI: 1.00– 1.01; P < 0.001), proximal stone location (AOR: 15.13; 95% CI: 1.52– 51.13; P = 0.020), moderate (AOR: 34.23; 95% CI: 8.28– 141.45; P < 0.001) and severe hydronephrosis (AOR: 33.75; 95% CI: 4.55– 250.36; P = 0.0006), and larger stone size (AOR: 1.51; 95% CI: 1.30– 1.75; P < 0.0001) as significant predictors of SFR failure. The S.T.O.N.E. score effectively predicts SFR failure, with an optimal threshold of > 8 achieving 85.0% accuracy. The model demonstrated 72.0% sensitivity, 81.0% specificity, and strong calibration. DCA indicated clinical utility, differentiating between low- and high-risk patients based on their S.T.O.N.E. scores. Conclusion: The S.T.O.N.E. score is a valuable tool for predicting post-ULT SFR, aiding preoperative decision-making and potentially improving surgical outcomes by identifying high-risk patients. Further validation in diverse populations is needed to confirm its clinical utility. Plain Language Summary: Ureteral lithotripsy (ULT) is a procedure used to treat ureteral stones; however, predicting the success of this treatment remains challenging for urologists. This study evaluates the S.T.O.N.E. score, a tool designed to estimate a patient’s likelihood of achieving stone-free status following ULT by considering factors such as stone size and location. Researchers analyzed data from 266 patients who underwent ULT at IBB University Hospitals between April 2021 and September 2023. The findings indicate that the S.T.O.N.E. score effectively predicts the presence of residual stones post-treatment. These results suggest that the score may assist urologists in making more informed decisions prior to surgery, particularly for patients at elevated risk. However, further research is necessary to validate its applicability across diverse patient populations.
- Open Access
- 29 October 2024
- Published by PAGEPress Publications in Archivio Italiano di Urologia e Andrologia
- Vol. 96 (4) , 12833
Effect of DOPA decarboxylase inhibitor supplements on the incidence of urinary tract infections in Parkinson’s disease patients: A systematic review and meta-analysis of randomized controlled trials
Objectives: Parkinson’s disease is the most common neurodegenerative disease. Combining levodopa with other drugs, including decarboxylase inhibitors (DCI) is its most effective treatment. Urinary tract infection (UTI) is the most common cause of hospitalization in Parkinson’s patients, making it crucial to find an appropriate treatment to reduce the incidence of this complication. This study aimed to investigate UTIs in Parkinson’s patients using levodopa with DCI supplements. Methods: In this systematic review and meta-analysis, databases such as PubMed, Scopus, Embase, Cochrane, and Web of Science were searched up to March 2024. Only randomized controlled trials involving Parkinson’s patients were included in the present study. Parkinson’s patients who used levodopa along with carbidopa or benserazide were considered the intervention group, while those who used levodopa with another drug were considered the control group.Results: Nine interventional studies were ultimately analyzed. The relative risk (RR) of UTI in patients taking DCI was 26% lower than those who did not (RR Treatment/Control = 0.74, 95% CI: 0.58-0.95, p = 0.019). Furthermore, observations at different times of follow-up showed that at 13-24 weeks and at > 24 weeks of treatment with DCI, there was a reduction in the incidence of UTI (RR = 0.68, 95% CI: 0.46-1.01 and RR = 0.77, 95% CI: 0.58-1.0, respectively). On the contrary, there was an increase of the risk of UTI in the first 12 weeks of treatment with DCI (RR = 1.11, 95% CI: 0.37-3.33). Conclusions: The results of this study indicated that using DCI drugs is associated with a reduced relative risk of developing UTIs. The beneficial effect of the drug showed after 12 weeks of treatment after an initial negative effect on the risk of UTI.
- 29 October 2024
- Published by PAGEPress Publications in Archivio Italiano di Urologia e Andrologia
- Vol. 96 (4) , 12833
Open AccessEffect of DOPA decarboxylase inhibitor supplements on the incidence of urinary tract infections in Parkinson’s disease patients: A systematic review and meta-analysis of randomized controlled trials
Objectives: Parkinson’s disease is the most common neurodegenerative disease. Combining levodopa with other drugs, including decarboxylase inhibitors (DCI) is its most effective treatment. Urinary tract infection (UTI) is the most common cause of hospitalization in Parkinson’s patients, making it crucial to find an appropriate treatment to reduce the incidence of this complication. This study aimed to investigate UTIs in Parkinson’s patients using levodopa with DCI supplements. Methods: In this systematic review and meta-analysis, databases such as PubMed, Scopus, Embase, Cochrane, and Web of Science were searched up to March 2024. Only randomized controlled trials involving Parkinson’s patients were included in the present study. Parkinson’s patients who used levodopa along with carbidopa or benserazide were considered the intervention group, while those who used levodopa with another drug were considered the control group.Results: Nine interventional studies were ultimately analyzed. The relative risk (RR) of UTI in patients taking DCI was 26% lower than those who did not (RR Treatment/Control = 0.74, 95% CI: 0.58-0.95, p = 0.019). Furthermore, observations at different times of follow-up showed that at 13-24 weeks and at > 24 weeks of treatment with DCI, there was a reduction in the incidence of UTI (RR = 0.68, 95% CI: 0.46-1.01 and RR = 0.77, 95% CI: 0.58-1.0, respectively). On the contrary, there was an increase of the risk of UTI in the first 12 weeks of treatment with DCI (RR = 1.11, 95% CI: 0.37-3.33). Conclusions: The results of this study indicated that using DCI drugs is associated with a reduced relative risk of developing UTIs. The beneficial effect of the drug showed after 12 weeks of treatment after an initial negative effect on the risk of UTI.
- Open Access
- 1 May 2022
- Published by Taylor & Francis in Research and Reports in Urology
- Vol. ume 14, 219-223
Use of Temporary Membrane-Covered Self-Expandable Metallic Stent – UVENTATM for Treatment of Recurrent Bulbar Urethral Stricture
Introduction: Recurrent urethral stricture is a real challenge. Interestingly use of temporary double layered self-expanding nitinol urethral stent with polytetrafluoroethylene (PTFE) membrane coating (UventaTM, Taewoong Medical, South Korea) has been recently reported with promising short-term results in recurrent urethral stricture. However most of the reported studies are published as abstracts of either case reports or case series of miniscule numbers. The aim of our study is to evaluate the outcome of this temporary urethral stent in patients with recurrent urethral stricture after urethroplasty as well as after multiple visual internal urethrotomy. Materials and Methods: In this retrospective study, 22 patients had placement of double-layered self-expanding stent with PTFE membrane coating (Uventa, Taewoong Medical) for recurrent bulbar strictures. The present study included cases between 2017 and 2020. The stricture in each patient were evaluated with Uroflowmetry and ascending urethrography. The data of demographic and clinical characteristics included age, aetiology, location and length of stricture, along with maximum urinary flow rate (Qmax), number of previous interventions, and stent-related complications. Results: The overall clinical success was achieved in 13/22 (59.1%) of patients at a median follow-up of 17 months (range 2– 44). The mean maximum urine flow rates were 7.07 ± 3.55mL/sec, 23.50 ± 10.41mL/sec, 21.41± 15.55 mL/sec, 14.88 ± 9.77 and 17.63 ± 12.28 mL/sec before, while stent in place, at 3 months, 6 months and 12 months after the procedure, respectively. Conclusion: In our study, the success rate of temporary urethral stent placement has remained at 59.1% at a median follow-up of 17 months. We conclude that further randomized controlled studies with long-term follow up are required to fully evaluate the outcome.
- 1 May 2022
- Published by Taylor & Francis in Research and Reports in Urology
- Vol. ume 14, 219-223
Open AccessUse of Temporary Membrane-Covered Self-Expandable Metallic Stent – UVENTATM for Treatment of Recurrent Bulbar Urethral Stricture
Introduction: Recurrent urethral stricture is a real challenge. Interestingly use of temporary double layered self-expanding nitinol urethral stent with polytetrafluoroethylene (PTFE) membrane coating (UventaTM, Taewoong Medical, South Korea) has been recently reported with promising short-term results in recurrent urethral stricture. However most of the reported studies are published as abstracts of either case reports or case series of miniscule numbers. The aim of our study is to evaluate the outcome of this temporary urethral stent in patients with recurrent urethral stricture after urethroplasty as well as after multiple visual internal urethrotomy. Materials and Methods: In this retrospective study, 22 patients had placement of double-layered self-expanding stent with PTFE membrane coating (Uventa, Taewoong Medical) for recurrent bulbar strictures. The present study included cases between 2017 and 2020. The stricture in each patient were evaluated with Uroflowmetry and ascending urethrography. The data of demographic and clinical characteristics included age, aetiology, location and length of stricture, along with maximum urinary flow rate (Qmax), number of previous interventions, and stent-related complications. Results: The overall clinical success was achieved in 13/22 (59.1%) of patients at a median follow-up of 17 months (range 2– 44). The mean maximum urine flow rates were 7.07 ± 3.55mL/sec, 23.50 ± 10.41mL/sec, 21.41± 15.55 mL/sec, 14.88 ± 9.77 and 17.63 ± 12.28 mL/sec before, while stent in place, at 3 months, 6 months and 12 months after the procedure, respectively. Conclusion: In our study, the success rate of temporary urethral stent placement has remained at 59.1% at a median follow-up of 17 months. We conclude that further randomized controlled studies with long-term follow up are required to fully evaluate the outcome.